Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers.
The expression level of the HER family is unreliable as a predictive marker for targeted therapies in cancer. Thus, there is a need to develop other biomarkers, which can be used to accurately select responsive patients for targeted therapies. The HER dimerization status may be more important than H...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1826263590743572480 |
|---|---|
| author | Waterhouse, B Gijsen, M Barber, P Tullis, I Vojnovic, B Kong, A |
| author_facet | Waterhouse, B Gijsen, M Barber, P Tullis, I Vojnovic, B Kong, A |
| author_sort | Waterhouse, B |
| collection | OXFORD |
| description | The expression level of the HER family is unreliable as a predictive marker for targeted therapies in cancer. Thus, there is a need to develop other biomarkers, which can be used to accurately select responsive patients for targeted therapies. The HER dimerization status may be more important than HER receptor expression per se in determining sensitivity or resistance to a given therapeutic agent. The aim of the study is to develop a FRET assay using dye conjugated secondary antibodies to assess HER receptor dimerization. Using primary antibodies from different species in conjunction with Alexa488 and Alexa546 conjugated secondary antibodies, we validated our EGFR/HER2 dimerization assay in three cell lines, EGFR positive A431 cells as well as HER2 positive breast cell lines BT474 and SKBR3 cells. Finally, we applied our assay to assess EGFR/HER2 dimerization in paraffin embedded cell pellets. Our results show promise for the assay to be applied to tumor samples in order to assess the prognostic significance and predictive value of HER receptor dimerization in various cancers. |
| first_indexed | 2024-03-06T19:54:13Z |
| format | Journal article |
| id | oxford-uuid:24fe5cb6-d1fd-473c-badb-760f11aa79aa |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:54:13Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:24fe5cb6-d1fd-473c-badb-760f11aa79aa2022-03-26T11:53:17ZAssessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:24fe5cb6-d1fd-473c-badb-760f11aa79aaEnglishSymplectic Elements at Oxford2011Waterhouse, BGijsen, MBarber, PTullis, IVojnovic, BKong, AThe expression level of the HER family is unreliable as a predictive marker for targeted therapies in cancer. Thus, there is a need to develop other biomarkers, which can be used to accurately select responsive patients for targeted therapies. The HER dimerization status may be more important than HER receptor expression per se in determining sensitivity or resistance to a given therapeutic agent. The aim of the study is to develop a FRET assay using dye conjugated secondary antibodies to assess HER receptor dimerization. Using primary antibodies from different species in conjunction with Alexa488 and Alexa546 conjugated secondary antibodies, we validated our EGFR/HER2 dimerization assay in three cell lines, EGFR positive A431 cells as well as HER2 positive breast cell lines BT474 and SKBR3 cells. Finally, we applied our assay to assess EGFR/HER2 dimerization in paraffin embedded cell pellets. Our results show promise for the assay to be applied to tumor samples in order to assess the prognostic significance and predictive value of HER receptor dimerization in various cancers. |
| spellingShingle | Waterhouse, B Gijsen, M Barber, P Tullis, I Vojnovic, B Kong, A Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. |
| title | Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. |
| title_full | Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. |
| title_fullStr | Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. |
| title_full_unstemmed | Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. |
| title_short | Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers. |
| title_sort | assessment of egfr her2 dimerization by fret flim utilizing alexa conjugated secondary antibodies in relation to targeted therapies in cancers |
| work_keys_str_mv | AT waterhouseb assessmentofegfrher2dimerizationbyfretflimutilizingalexaconjugatedsecondaryantibodiesinrelationtotargetedtherapiesincancers AT gijsenm assessmentofegfrher2dimerizationbyfretflimutilizingalexaconjugatedsecondaryantibodiesinrelationtotargetedtherapiesincancers AT barberp assessmentofegfrher2dimerizationbyfretflimutilizingalexaconjugatedsecondaryantibodiesinrelationtotargetedtherapiesincancers AT tullisi assessmentofegfrher2dimerizationbyfretflimutilizingalexaconjugatedsecondaryantibodiesinrelationtotargetedtherapiesincancers AT vojnovicb assessmentofegfrher2dimerizationbyfretflimutilizingalexaconjugatedsecondaryantibodiesinrelationtotargetedtherapiesincancers AT konga assessmentofegfrher2dimerizationbyfretflimutilizingalexaconjugatedsecondaryantibodiesinrelationtotargetedtherapiesincancers |